What Is VYNE Therapeutics Inc. (VYNE) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, VYNE Therapeutics Inc.'s intrinsic value is estimated at $0.88, presenting a divided outlook at the current price of $0.76. With an average implied return of +16.4% across a split 3–3 (bull–bear) consensus, the model spread of +244.7% underscores analytical uncertainty. Notably, Dynamic NAV sees the most upside at +164.1% (fair value: $2.00), while ML-RIV is the most conservative at -80.6% ($0.15). The spread between these extremes — +244.7% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About VYNE?
9 of 13 models are currently active for VYNE. Of these, 5 models suggest upside while 4 models suggest overvaluation. The Bayesian DCF estimates VYNE's intrinsic value at $0.58, implying -23.2% downside from the current price. See which stocks rank higher →
How Does VYNE Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, VYNE ranks #316 by Quality of Company score. CirclFi's QOC score of 4.2/10 evaluates 32 fundamental signals. A score of 4.2 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
The Pharmaceutical Preparations sector introduces analytical considerations specific to healthcare company businesses. For VYNE Therapeutics Inc., metrics like FDA approval probability provide important context that general-purpose valuation models may underweight.
Is VYNE a Value Trap?
CirclFi's Value Trap algorithm assigns VYNE a score of 44/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for VYNE Therapeutics Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, VYNE Therapeutics Inc. scores 4.2 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +244.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every VYNE valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across VYNE's 9 active models, average confidence is 23%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad